Abstract
Ovarian function suppression (OFS) an old endocrine therapy has been tested in premenopausal women with early breast cancer (EBC) but not widely accepted in modern practice. The question is re-addressed in recent big trials, however the big dilemma doesn't resolved. This perspective touch upon the ancient as well as current evidence of OFS in these young early breast cancer women and try to enlighten the readers further on this controversial topic wherein there is lots of light but little illumination.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
